There are still thousands of persons today who cannot get their blood pressure under control, regardless of massive medications taken daily. An experimental treatment just may be the hope for thousands to finally maintain their blood pressure.
A non-medication and only slightly invasive treatment that sends radio waves through the use of a catheter to probe blast that shuts down nerves in the kidney arteries. This treatment seems to decrease blood pressure in those patients whose medications just is not effecting their blood pressure.
The trail named Simplicity HTN-2 for short, which is headed by Dr. Murray Esler, associate director of the Barker IDI Heart and Diabetes Institute in Melbourne, Australia. This trail is the first human minimally invasive method which is named renal denervation or RDN for therapeutic means.
Nearly one billion persons world wide have high blood pressure with readings of 140/90 and even higher. A vast majority require three to four different medications in order to keep it under control. At least 10% of the persons regardless of taking medications still cannot keep their high blood pressure maintained. Even with medications that relax the blood, stop water and salt retention. Figures have shown that one in five persons even with medications are still at great risk for stroke, heart attack and other problems because treatments are not decreasing their blood pressure low enough.
In the trail, Dr. Elser and associates discovered that by suppressing the nerves near the kidneys greatly lowers blood pressure in those patients where the blood pressure was still to high even after taking five different types of medications to attempt to get control.
The RND procedure involves physicians inserting a catheter-based probe in a artery located in the groin. Then the probe is directed upwards into the renal artery where it sends a short blast of high frequency waves that contain enough energy to diminish small nerves which run along the lining of the renal arteries and that are associated to high blood pressure.
For this trail 106 patients were randomly assigned to receive either RDN plus medications (52 patients) or just medications (54 patients). The average age of patients was 58 years old of which 35% were female and 97% Caucasian.
Blood pressure measurements consist of two numbers such as 140/90 mm Hg which stands for millimeters of mercury. The first number is the systolic pressure meaning the pressure that is against the artery wall when the heart beats. The second number is diastolic which is the pressure between the heart beats.
At the beginning of the trail patients basically had the same blood pressure reading of 178/98 in the treatment group as opposed to 178/97 for controls.
After a period of six months of the procedure blood pressure reading on the systolic pressure decreased by 33 points. The diastolic had decreased by 12 points.
When the news of this treatment had been released to the pressure Dr. Esler stated they just had finished information on 48 patients who received the RDN treatment. Among those patients 93.8 % had a decrease of at least five percent in systolic pressure. Also, almost 39% of the treatment group had a decrease in blood pressure below 140/90. This is the borderline that is usually used as a mark in hypertension treatment. That number is larger than 120/80 which is considered a normal blood pressure in adults.
Dr. Esler notes that it is extremely rare for persons who have severe drug resistance high blood pressure to obtain the target pressure with just medications.
Dr. Esler also notes the following:
A small amount of patients after treatment that some of their medications could be reduced and in some cases even discontinued.
This new treatment is very safe and effective in diminishing the nerves for a time span of six months and possibly it could permanent.
This method gives an innovative non-medication treatment for patients with high blood pressure that is not reacting moderately to numerous hypertension medications.
Dr. Elser does state that even though most of the participants in the study were Caucasian he feels the results would remain the same on all ethnically various groups.
The researchers had not discovered any serious device or side effects and there were no cardiovascular or kidney associated issues.
Dr. Suzanne Oparil, Director of Vascular Biology and Hypertension Program with the University of Alabama, Birmingham, states this study was vital and had many great strengths with possibility of actually modernizing treatment for resistant hypertension.
Dr. Jeremy Pearson, professor and associate director of the British Heart Foundation notes this is an inspiring new method for treating patients with high blood pressure where medications produce no effects.
The British Heart Foundation remarked they had hopes that the study bring about new treatments to decrease the illnesses and deaths associated to high blood pressure.
Dr. Elliott Antman, a cardiologist at Women’s Hospital and vice chairman of the American Heart Association in Chicago, where this studies results had been given this week, states he is very interested in this study. Even if this treatment cannot cure high blood pressure and only is halfway successful, it is still of great benefit to persons at dire risks of heart attacks, strokes and death due to the fact the medications do not give enough aide to lowering their high blood pressure.
The stability of the treatment also improves blood sugar control which is great for diabetics with high blood pressure. This provides those patients with a whole new treatment.
This new treatment is being manufactured by Ardian, Inc., a private company which is housed in Mountain View, California. The investors for this treatment includes the world’s largest medical technology company, Medtronic, Inc. This treatment had been granted approval two years prior in Europe. It is currently becoming available for broader use as physicians there are trained to do this procedure.
This treatment cost $14,000 in Europe but no treatment price has been set yet in the United States. A study which is geared at the United States for gaining its approval will begin next year. Andrew Cleeland states that 200 United States medical facilities have called to become part of this new treatment.
In an study done earlier, those patients who had this treatment done 2 ½ years ago still show improvement in their blood pressure.
Dr. Mariell Jessup, head of the heart failure center at the University of Pennsylvania and chairperson for the heart conference notes this treatment is something that practitioners have always wished for, some method to cure high blood pressure. Patients will need to be observed for a long time to make sure the treatment will last.
So far the treatment does seem to last. Dorian Blair age thirty-seven and a father of two who resides in Cleveland, has a strong family history of high blood pressure. Mr. Blair has had five heart attacks and mini strokes in about the last five years. His blood pressure was at the 180 to 190 range. Last December, he had underwent the treatment. His current number is still around 140. He had stated the treatment was easy and he was up and walking around the very next day.
Medical News Today